Anti-FXI antibody [EPR29204-87],Abcam,AB323450

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

Dot, WB

Platform ID

BAB248813599

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-FXI antibody [EPR29204-87]
Cat. No.AB323450
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationDot, WB
ClonalityMonoclonal
Clone NumberEPR29204-87
Concentration0.493 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. See full target information F11

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.